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the incidence of bursitis “pes anserinum” in patients with OA of knee
joints, its association with ﬂat-foot and the inﬂuence of complex treatment
with the use of insoles during disease’s course.
Methods: Patients consulted a rheumatologist on the occasion of wors-
ening the course of the disease. 52 patients with OA of knee joints
were examined. All patients were administered clinical and instrumental
examinations which included objective examination, full blood count,
urinalysis, blood serum creatinine, serum glutamic transaminase, serum
asparagines transaminase, the X-ray of knee joints, the ultrasonic exam-
ination of knee joints and periarticular tissues using the Sonoline G 50
device.
Results: The initial examination showed that most patients – 43 (82%)
had had a chronic recurrent course of the disease that had made them
take non-steroid anti-inﬂammatory medicines and use ointments. X-ray
stage I of the disease (Kellgren and Lawrence, 1957) was diagnosed in
10 (19%) patients, stage II and stage III – in 26 (50%) and 16 (31%)
patients respectively. Women (mean age 63) constituted 85% of the
whole patient’s group. The given proportion of women corresponded to
the epidemiological ﬁndings. On the average, all patients had a 6-year
history of the disease. Swelling of knee joints, tenderness along the
articular space and the periarticular area on the medial side were revealed
on palpation. The activity of the disease was evaluated by the patients
according to 100mm visual analogue scale (VAS). It was assessed by
the rheumatologist by the same scale. Pain at rest, pain during motion,
the quality of life were estimated by means of the questionnaire (HAG).
Bursitis “pes anserinum” was revealed in 22 (42%) patients, mainly with
stage II of knee joints’ OA and conﬁrmed by the ultrasonic examination of
the joints. Women’s mean age in this group was 66 years, all women were
overweighed. The diagnosis of combined (mainly longitudinal) stage I and
stage II ﬂat-foot in these patients was conﬁrmed by stereoplantopodog-
raphy and aroused their great interest invariably. When being asked the
patients said that they had experienced pain in their feet and tiredness of
their legs by the end of the day. The patients considered it to be natural
phenomenon which did not require any treatment. Complex non-medical
treatment included individual approach to every patient, wearing insoles
to correct ﬂat-foot, which enabled to improve the functional activity of
their knee joints, and was noted by the patients. Medical therapy was
identical for all patients and consisted of a non-steroid anti-inﬂammatory
medicine, intrajoint corticosteroids according to indications, periarticular
corticosteroids in the area of “pes anserinum”, physiotherapeutic treat-
ment (magnet therapy) and a symptomatic medicine of a slow action.
The received ﬁndings demonstrated a decrease of pain by 61mm (VAS)
and an improvement of the life quality by 4.7 points 10 days after the
treatment.
Conclusions: The correction of ﬂat-foot by means of knee joints’ OA
complex treatment enables to reduce the overload on the medial group of
femoral muscles and to stabilize the shin that abates the disease activity
and prolongs a stable course of the disease. The received ﬁndings have
revealed a low level of knowledge about ﬂat-foot as about a problem
which inﬂuences the normal functioning of feet and knee joints.
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Purpose:We asked if patients with metabolic syndrome (MS) undergoing
total knee arthroplasty (TKA) have an increased risk for symptomatic
deep vein thrombosis (DVT).
Methods: We surveyed 1460 consecutive patients undergoing primary
TKA for relevant covariates. Metabolic syndrome was deﬁned as body
mass index above 30 kg/m2, diabetes, hypertension, and hypercholes-
terolemia.
Results: The overall incidence of symptomatic DVT was 4.4% (65/1460).
Patients with MS had an increased incidence of DVT as compared
to those without MS (15.5% vs 3.4%). Adjusted analysis showed that
MS increased the risk of symptomatic DVT by 4.2 (95% CI [1.5, 11.4],
p = 0.006) times compared to those without MS.
Conclusions: Protocols developed for prophylactic anti-coagulation
should give consideration to patients with metabolic syndrome.
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Purpose: Investigation into the long term duration of beneﬁt after
ultrasound-guided intra-articular injection of Hyalubrix ® in patient with
hip OA.
Background: HYAP15 (Hyalubrix®) is a sterile, non pyrogenic, viscoelas-
tic solution manufactured with hyaluronic acid sodium salt for intra-
articular injection, obtained by bacterial fermentation from fraction of
high molecular weight (>1500 kDa) having Sodium hyaluronate 15mg/ml.
Hyalubrix® is marketed in Italy, Austria and Germany for the treatment of
degenerative or mechanical arthropathy and it is mainly used for the treat-
ment of the knee OA patients. A post marketing study on 1523 patients
affected by knee or hip OA supported the efﬁcacy and safety behaviour
of Hyalubrix® in pain reduction and functionality improvement. Literature
data regarding hip joint viscosupplementation are at now still limited to
small studies. We previously performed a comparative study for Hyalubrix
vs Carbocaine with a follow up of six months with good results in terms
of efﬁcacy and safety for Hyalubrix. Neverthless, at now there are no post
marketing cohort studies on hyalubrix in hip OA.
Methods: 344 adults, ambulatory patients suffering from hip OA grade 1
to 3 according to Kellgren and Lawrence were considered eligible for
the study. Patients were injected with two syringes (4ml) of Hyalubrix,
repeated every six month, and in some cases, if clinically requested, every
three months, under ultrasound guidance. A 3.5MHz convex transducer
was used with a sterilised biopsy guide attached. The hip joint was
scanned by means of an anterior parasagittal approach. The efﬁcacy
of the injection was assessed by using the Lequesne index and VAS pain
score at baseline and, then, every three months after the ﬁrst injection.
NSAIDs consumption was also evaluated during the month before the
injection and, then, every three months after ﬁrst the injection of Hylubrix
until to 18 months. Safety was assessed by recording any adverse event
during the follow up period.
Efﬁcacy of IA US-guided Hip injection of Hyalubrix® in OA affected
patients.
Table 1 Variations of the assessment criteria after repeated IA injections of Hyalubrix.
Baseline
(N=344)
3 months
(N=256)
6 months
(N=212)
9 months
(N=168)
12 months
(N=149)
15 months
(N=129)
18 months
(N=119)
OA pain VAS 5.8 4.3* 4.2* 4.1* 4.2* 4.1* 4.3*
NSAID
consumption
(Days/month)
6.7 4.4* 2.9* 3.2* 3.6* 3.8* 3.6*
Lequesne
index
7.5 5.6* 4.9* 5.0* 5.5* 5.6* 5.6*
*p< 0.01.
Results: 344 patients were treated, 166M and 177F. 32 had bilateral hip
OA. 8 patients left the study to undergo to hip replacement. 97 patients
are lost to follow up. No local or systemic adverse events were reported.
A statistically signiﬁcant reduction was observed at all time points versus
baseline for all assessment criteria, p< 0.01 (Tab. 1 and Fig. 1).
